DeepMed Research

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer

Phase 2

Conditions: Pancreatic Neoplasms

Interventions: Drug: Nab paclitaxel and S-1

First Posted Date: 2021-03-22

Last Posted Date: 2021-03-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 72

Registration Number: NCT04808687

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Phase 3

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Biological: Pembrolizumab
Radiation: neoadjuvant chemoradiotherapy
Drug: Paclitaxel
Drug: Cisplatin

First Posted Date: 2021-03-19

Last Posted Date: 2022-06-01

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 342

Registration Number: NCT04807673

Locations: 🇨🇳
Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Study on the Peristaltic Direction of GI Anastomosis in Roux-en-Y Reconstruction

Not Applicable

Conditions: Peristaltic Direction
Roux-en-Y Gastrointestinal Anastomosis
Gastric Cancer

Interventions: Procedure: Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction

First Posted Date: 2021-03-17

Last Posted Date: 2022-03-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 148

Registration Number: NCT04801459

Locations: 🇨🇳
Cancer Hospital of Tianjin Medical University, Tianjin, China

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC

Phase 3

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Anlotinib
Drug: Icotinib

First Posted Date: 2021-03-15

Last Posted Date: 2021-03-15

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 206

Registration Number: NCT04797806

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Disease-free Survival Rate

Interventions: Drug: Camrelizumab+Chemotherapy+Chemoradiotherapy

First Posted Date: 2021-03-04

Last Posted Date: 2021-03-04

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 59

Registration Number: NCT04782765

Locations: 🇨🇳
Peiguo Wang, Tianjin, Tianjin, China

A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer

Phase 4

Conditions: TTP

Interventions: Drug: PYRROTINI
Radiation: Brain radiation therapy

First Posted Date: 2021-02-23

Last Posted Date: 2021-02-23

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 43

Registration Number: NCT04767828

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor

Phase 4

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: albumin-bound paclitaxel

First Posted Date: 2021-02-23

Last Posted Date: 2021-02-23

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 116

Registration Number: NCT04766827

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

Phase 2

Recruiting

Conditions: Sintilimab, Cetuximab, Regorafenib,Combine,mCRC

Interventions: Drug: KRAS BRAF mutant Sintilimab + regafinil
Drug: Sintilimab，regofinib，cetuximab

First Posted Date: 2021-02-09

Last Posted Date: 2023-02-14

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 90

Registration Number: NCT04745130

Locations: 🇨🇳
Rui Liu, Tianjin, Tianjin, China

Prevention and Treatment of Pyrrolitinib-associated Diarrhea

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Loperamide
Drug: Loperamide and montmorillonite powder
Drug: Loperamide and golden bifid

First Posted Date: 2021-02-03

Last Posted Date: 2021-02-03

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 470

Registration Number: NCT04736186

Locations: 🇨🇳
TianJin Medical University Cancer Institute and Hospital, Tianjin, China

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Phase 2

Conditions: Metastatic Breast Cancer
Advanced Breast Cancer

Interventions: Drug: SHR6390
Drug: famitinib

First Posted Date: 2021-02-02

Last Posted Date: 2023-04-13

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 35

Registration Number: NCT04733417

Locations: 🇨🇳
Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy